POTENCY OF LUTEOLIN WITH SOLID LIPID NANOPARTICLE (SLN)-POLYETHYLENE GLYCOL (PEG) MODIFICATION FOR ARTEMISININ-RESISTANT PLASMODIUM FALCIPARUM INFECTION

William Kamarullah, Erika Indrajaya, Janice Emmanuella

= http://dx.doi.org/10.20473/ijtid.v7i3.6726
Abstract views = 451 times | downloads = 418 times

Abstract


Falciparum malaria is still considered as one of the important global health problems and its causal agent (Plasmodium falciparum) is reported to be the third most common factor for contributing the number of deaths in the world. As we all know, Artemisinins are
the most rapidly acting of currently available antimalarial drugs. Along with Artesunate, these two combining drugs, the so-called Artemisinin-based combination therapies (ACTs) has become the foundation of modern falciparum malaria treatment globally. Nowadays, however, there have been reports about intricate cases of resistance against Artemisinin in various Southeast Asian countries and it is predicted to spread over several other countries, including Indonesia. Therefore, adjuvant therapy is required along with first-line therapy administration to help eradicate both Artemisinin-sensitive and resistant P. falciparum. Luteolin in vitro has a prospective inhibitory activity (IC50<50 μg) in inhibiting the development of parasite’s life cycle. Nonetheless, its poor bioavailability and pharmacokinetics restrict clinical application. The low bioavailability of luteolin requires encapsulation using solid lipid nanoparticle (SLN) and polyethylene glycol (PEG). SLN is useful for improving the bioavailability of luteolin in the body, whereas PEG is needed in order to prevent the destruction of luteolin-SLN substance by the reticuloendothelial system. Here in this literature review, we’re trying to demonstrate the benefits, potential, way of constructions, pharmacokinetics, and pharmacodynamics of luteolin encapsulated with SLN with PEG modification. Thus, it is hoped that the results of this literature study may encourage further research in assisting the development of adjuvant therapy for cases of Artemisinin-resistant P. falciparum infection.


Keywords


luteolin, Plasmodium falciparum, Artemisinin resistance, SLN, PEG

Full Text:

PDF

References


REFERENCES

Kementrian Kesehatan Republik Indonesia. Riskesdas 2013. 2013.

Teuscher F, Chen N, Kyle DE, Gatton ML, Cheng Q. Phenotypic changes in artemisinin-resistant Plasmodium falciparum lines in vitro: Evidence for decreased sensitivity to dormancy and growth inhibition. Antimicrob Agents Chemother. 2012;56(1):428–31.

Witkowski B, Amaratunga C, Khim N, Sreng S, Chim P, Kim S, et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect Dis. 2013 Dec;13(12):1043–9.

Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of Artemisinin Resistance in Plasmodiumfalciparum Malaria. N Engl J Med. 2014;371(5):411–23.

KH M, S M. Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. J Agric Food Chem. 2001;49(3):106–3112.

Tasdemir D, Lack G, Brun R, Rüedi P, Scapozza L, Perozzo R. Inhibition of Plasmodium f alciparum Fatty Acid Biosynthesis: Evaluation of FabG, FabZ, and FabI as Drug Targets for Flavonoids. J Med Chem. 2006 Jun;49(11):3345–53.

AM L, KJ S. Common dietary flavonoids inhibit the growth of the intraerythrocytic malaria parasite. BMC Res Notes. 2015;1(26).

Dang H, Meng MHW, Zhao H, Iqbal J, Dai R, Deng Y, et al. Luteolinloaded solid lipid nanoparticles synthesis, characterization, & improvement of bioavailability, pharmacokinetics in vitro and vivo studies. J Nanoparticle Res. 2014 Apr 16;16(4):2347.

Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine. 2007;2(3):289–300.

Teuscher F, Gatton ML, Chen N, Peters J, Kyle DE, Cheng Q. ArtemisininInduced Dormancy in Plasmodium falciparum ; Duration, Recovery Rates, and Implications in Treatment Failure. J Infect Dis. 2010 Nov;202(9):1362–8.

Witkowski B, Khim N, Chim P, Kim S, Ke S, Kloeung N, et al. Reduced artemisinin susceptibility of plasmodium falciparum ring stages in western cambodia. Antimicrob Agents Chemother. 2013;57(2):914–23.

Hien T, Thuy-Nhien N, Phu N, Boni MF, Thanh N, Nha-Ca N, et al. In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam. Malar J. 2012;11(1):355.

Kyaw MP, Nyunt MH, Chit K, Aye MM, Aye KH, Aye MM, et al. Reduced Susceptibility of Plasmodium falciparum to Artesunate in Southern Myanmar. Borrmann S, editor. PLoS One. 2013 Mar 8;8(3):e57689.

Mita T, Tachibana S-I, Hashimoto M, Hirai M. Plasmodium falciparum kelch 13 : a potential molecular marker for tackling artemisinin-resistant malaria parasites. Expert Rev Anti Infect Ther. 2016 Jan 2;14(1):125–35.

Woodrow CJ, White NJ. The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. van Ooij C, editor. FEMS Microbiol Rev. 2017 Jan;41(1):34–48.

Shimoi K, Saka N, Nozawa R, Sato M, Amano I, Nakayama T, et al. Deglucuronidation of a flavonoid, luteolin monoglucuronide, during inflammation. Drug Metab Dispos. 2001 Dec;29(12):1521–4.

Qidwai T, Khan F. Antimalarial Drugs and Drug Targets Specific to Fatty Acid Metabolic Pathway of Plasmodium falciparum. Chem Biol Drug Des. 2012 Aug;80(2):155–72.

Thilakarathna SH, Rupasinghe HPV. Flavonoid bioavailability and attempts for bioavailability enhancement. Nutrients. 2013 Aug 28;5(9):3367–87.

Kesarwani K, Gupta R, Mukerjee A. Bioavailability enhancers of herbal origin: an overview. Asian Pac J Trop Biomed. 2013 Apr;3(4):253–66.

Ekambaram P, Sathali a AH, Priyanka K. Solid Lipid Nanoparticles : a Review. Sci Rev Chem Commun. 2012;2(1):80–102.

C B, O C, R C, L G, A M, MR G. Phagocytic uptake of fluorescent stealth and non-stealth Solid lipid nanoparticles. Int J Pharm. 2001;175:185–193.

Journal AI. An Indian Journal. Biochemistry. 2011;5(2):7–10.

WB J. The origin of the soxhlet extractor. J Chem Educ. 2007;84:1913.

Singh H. Nanotechnology Applications in Functional Foods; Opportunities and Challenges. Prev Nutr Food Sci. 2016 Mar 31;21(1):1–8.

Vijayakumar A, Baskaran R, Jang YS, Oh SH, Yoo BK. Quercetin-Loaded Solid Lipid Nanoparticle Dispersion with Improved Physicochemical Properties and Cellular Uptake. AAPS PharmSciTech. 2017 Apr 1;18(3):875–83.

Jawahar N, Meyyanathan SN, Reddy G, Sood S. Solid lipid Nanoparticles for Oral delivery of Poorly Soluble Drugs. J Pharm Sci Res. 2012;4(7):1848–55.

Mukherjee S, Ray S, Thakur R. Solid lipid nanoparticles: A modern formulation approach in drug delivery system. Indian J Pharm Sci. 2009;71(4):349.

Das S, Chaudhury A. Recent Advances in Lipid Nanoparticle Formulations with Solid Matrix for Oral Drug Delivery. AAPS PharmSciTech. 2011 Mar 21;12(1):62–76.

Chen Z, Kong S, Song F, Li L, Jiang H. Pharmacokinetic study of luteolin, apigenin, chrysoeriol and diosmetin after oral administration of Flos Chrysanthemi extract in rats. Fitoterapia. 2012 Dec; 83(8):1616–22.


Refbacks

  • There are currently no refbacks.




Copyright (c) 2018 Indonesian Journal of Tropical and Infectious Disease

View My Stats

IJTID Indexed by : 

        

 
IJTID (pISSN 2085-1103eISSN 2356-0991is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Institute of Tropical Disease - Airlangga University
Gedung Lembaga Penyakit Tropis Lt.1, Kampus C Universitas Airlangga
Jln. Mulyorejo Surabaya 60115, Indonesia
E-mail: ijtid@itd.unair.ac.id